Compare Honeywell International Inc (HON) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs GeneDx Holdings Corp — how do they compare? Honeywell International Inc trades at $207.73 (market cap $65.48B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Honeywell International Inc is far larger — about 32.4× GeneDx Holdings Corp's market cap, and Honeywell International Inc pays a 1.36% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and GeneDx Holdings Corp for 19 Days on average.
| HON | WGS | |
|---|---|---|
Market Cap | $65.48B | $2.02B |
Volume | 2,047,782 | 734,640 |
Sector | Industrials | Health |
52-Week High | $248.79 | $167.51 |
52-Week Low | $188.14 | $34.51 |
Typical Hold Time | 91 Days | 19 Days |
Enterprise Value | $90.27B | $2.05B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $206.6, down 0.73% with bearish technical signals despite strong fundamental metrics including a low P/E of 7.94 and robust ROE of 47.43%. The company recently beat Q2 2026 EPS estimates and secured a $300 million refinery project, positioning for growth post-spinoff of its aerospace and advanced materials divisions. Analyst consensus remains strongly bullish with a $259.25 price target.
HON presents a compelling value opportunity with attractive valuation multiples and consistent earnings outperformance, though near-term technical weakness and increasing debt-to-asset ratios warrant caution. The company's strategic focus on automation and recent contract wins support long-term growth prospects despite cyclical industrial sector risks.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
